Centifolia 2011, the International Congress in Cosmetics and Perfumery, washeld in Grasse from October 19 to 21, 2011. It was an adventure open to all the stakeholders of the beauty industry (Executives, Sourcing Directors, R&D, Buyers, CSR, Production, Marketing, Communication, producers of ,…).
Any product carries and transmit a vision of the world, that which is inscribed in its gene and production. To buy a product (ingredient, service, finished product…), is to subscribe to this vision. To buy is to vote. Today, social media combined to mobility can celebrate or destroy a product and its brand, sometimes in a few days. Markets are becoming conscious.
So went the rationale of the Centifolia 2011 Congress. A good programme, with the following premium speakers: Claudie Ravel, director and founder of Guayapi Tropical ; Gauthier Chapelle, co-founder of Biomimicry Europa ; Xavier Ormancey, Yves Rocher ; Guillaume Flavigny, Givaudan ; Francis Kurkdjian, parfumer ; Ngub Nding, director of Ephyla 3, specialist of traditional medicines ; Marie-Laure Simonin Brau, Dessange International ; Jean-François Noubel and Fernanda Ibarra of the Collective Intelligence Research Institute (organisers) ; a few others ; and I, founder of Soléco.
Several of those speakers mentionned indigenous and local knowledge on biodiversity. I focused on this issue under two angles: international law and business.
The Convention on Biological Diversity (1993) offers a framework, adopted by many countries, for commercial partnerships between indigenous and local communities (ILC) and companies, respecting the autonomy of the latter, and their right to valorise their knowledge. However, the principles of prior informed consent and benefit sharing are very general. As we have show in previous articles (currently in French only), any commercial partnership involving local species and traditional knowledge ignites a dialogue between two worlds, which are extremely different. Thus, it is necessary to study the practical experience of partnerships between ILC and companies, in order to make out of them learnings and best practices. This is what I propose, by putting in evidence the main issues of those commercial partnerships, and inciting companies to improve their action and innovate in their business models related to biotrade.
Here is the conference: